2026 updates and upcoming trials in prostate cancer radiotherapy

Alison Tree, MBBS, FRCR, MD(res), The Royal Marsden NHS Foundation Trust, London, UK, gives an overview of recent advances in prostate cancer radiotherapy, including the potential of ultra-hypofractionation and stereotactic body radiotherapy (SBRT) to shorten treatment duration, as well as strategies to prevent bladder side effects and improve cure rates for high-risk patients. De-escalation studies such as the DESTINATION 1 (NCT06177093) and DESTINATION 2 (NCT06638541) trials aim to deliver higher doses to the tumor while sparing surrounding tissue. This interview took place at 2025 European Society for Medical Oncology (ESMO) Asia Congress in Singapore, Singapore. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.